Report Phase 3 data for ruxolitinib cream in atopic dermatitis

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 14 Feb 2019
Due: 31 Dec 2020
Delivered: April 2020

Deadline
Met
Late
Not met
Today

What the company said

“a Phase 3 program of ruxolitinib cream in patients with atopic dermatitis was initiated in December 2018. Data are expected to be available in 2020”

SourceIncyte Form 8-K press release, 2019-02-14
FilingSEC filing index
Deadline as statedin 2020
Deadline used31 Dec 2020, the last day of the stated period
TypeProject
Permanent referenceKI-C-2019-INCY-005653
Cite as https://keptindex.org/c/KI-C-2019-INCY-005653/ — this address never changes.

What we found

Evidence strength A What the grades mean

Phase 3 TRuE-AD data for ruxolitinib cream in atopic dermatitis were presented in April 2020, before the 2020 deadline, with both trials meeting primary endpoints.

A
Incyte 10-K filed 2021-02-09 Regulatory filing · published 9 Feb 2021 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In April 2020, safety and efficacy data from the two Phase III trials in the TRuE-AD program evaluating ruxolitinib cream in mild-to-moderate atopic dermatitis (AD) were presented at the Revolutionizing Atopic Dermatitis (RAD) virtual symposium; both trials met their primary endpoints.” ✓ confirmed on the page

Market reaction: the shares moved -9.3% against the S&P 500 over the three sessions around the disclosure (8 Feb 2021 to 11 Feb 2021). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift -275 days
2 versions

Version 1 · original · stated 14 Feb 2019

Deadline 31 Dec 2020 (“in 2020”) · wording expected
Version 2 · stated 13 Feb 2020

Deadline 31 Mar 2020 (“in the first quarter of 2020”) · wording expected

“The results of TRuE-AD1, the second of two Phase 3 trials required for regulatory submission, are anticipated to be available in the first quarter of 2020.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: Phase 3 ruxolitinib cream atopic dermatitis data
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.